Corrales, NM – April 24th 2017 – Indica Labs proudly announces its breakthrough HALO® Deep Learning technology excelled in the CameLyon17 diagnostic image analysis competition. The international challenge engaged commercial and academic teams worldwide to develop deep-learning algorithms to analyze 500 whole-slide H&E lymph node images and calculate TNM staging of 100 breast cancer patients. The HALO Deep Learning solution was the highest ranking commercial solution and third overall among 32 accepted teams.
Indica’s CEO Steven Hashagen remarked “Our team is excited to learn the results of the competition. Cancer staging is critical for determining a patient’s prognosis and treatment, yet it is a very complex task for both machine and pathologist. Our HALO platform is at the forefront of cancer research, cancer diagnostics, and improvement of patient outcome, yet we’re just scratching the surface of what will be accomplished with the technology.
The HALO Deep Learning system combines multiple Neural Network technologies which are seamlessly integrated into HALO, the industry-leading digital pathology platform. Indica Labs has rolled out beta-evaluations of the technology to several pharmaceutical companies, academic medical centers, and the National Cancer Institute. Official launch of the product is scheduled for July 2017. Deployment options include both cloud-based and on-premise configurations.
Full results and details of the CameLyon17 competition can be found at https://camelyon17.grand-challenge.org/results/. For more information, evaluation, and collaboration opportunities, please contact us at firstname.lastname@example.org.
About Indica Labs, Inc.
Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images. Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules. Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-therapy, oncology, metabolism, toxicological pathology, neuroscience and more.